Anticoagulation Issues in Patients with AF - 29/08/12
Corresponding author. Cardiovascular Department, Ospedale dell’Angelo, Via Paccagnella 11, 30174 Mestre- Venice, Italy.Résumé |
The evaluation of the risk of stroke for individual patients with atrial fibrillation (AF) is a crucial factor in the decision to provide anticoagulation therapy. Novel oral anticoagulants, as compared with warfarin, are associated with a lower or similar rate of stroke and systemic embolism and a lower rate of hemorrhagic stroke. These drugs are administered at a fixed dose, have a shorter peak action and half-life, and do not require international normalized ratio monitoring. After a successful AF ablation, oral anticoagulation therapy discontinuation seems to be feasible in patients with a CHADS2 score greater than or equal to 2 and normal left atrial (LA) function. However, larger prospective randomized trials are needed to confirm the safety of this strategy.
Le texte complet de cet article est disponible en PDF.Keywords : Atrial fibrillation, Anticoagulation, Stroke, Bleeding, Catheter ablation
Plan
Vol 4 - N° 3
P. 363-373 - septembre 2012 Retour au numéro
Article précédent
- Atrial Fibrillation Ablation Strategy : “Ready Made” or “Tailored”?
- Hamid Ghanbari, Hakan Oral
- AF Ablation : Do You Need a Mapping System for Ablation?
- Kojiro Tanimoto, Paul J. Wang, Amin Al-Ahmad
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?